Oppenheimer Asset Management Inc. Sells 59,293 Shares of Abbott Laboratories $ABT

Oppenheimer Asset Management Inc. reduced its position in Abbott Laboratories (NYSE:ABT) by 23.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 191,186 shares of the healthcare product maker’s stock after selling 59,293 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Abbott Laboratories were worth $25,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. IMG Wealth Management Inc. lifted its holdings in Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after purchasing an additional 167 shares in the last quarter. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories during the third quarter valued at approximately $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories in the third quarter worth $31,000. Anfield Capital Management LLC boosted its position in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC bought a new stake in Abbott Laboratories in the 2nd quarter valued at $32,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was purchased at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the purchase, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

ABT has been the subject of several research analyst reports. Oppenheimer cut their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Barclays lowered their price objective on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Daiwa Securities Group lowered their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Finally, Raymond James Financial decreased their price objective on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Stock Up 1.6%

Shares of NYSE:ABT opened at $110.86 on Monday. The firm has a market capitalization of $192.77 billion, a PE ratio of 29.80, a price-to-earnings-growth ratio of 1.76 and a beta of 0.75. The business has a 50 day simple moving average of $120.86 and a two-hundred day simple moving average of $126.91. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a $0.63 dividend. The ex-dividend date is Thursday, January 15th. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.